FDA gives Denali accelerated approval for rare disease drug
美国FDA向丹纳利疗法公司罕见病药物授予加速批准

The FDA granted accelerated approval to Denali Therapeutics’ rare disease drug Avlayah, bucking a recent trend of rejections in the space that has put the agency under political pressure.
美国食品药品监督管理局向丹纳利疗法公司的罕见病药物Avlayah授予加速批准，逆转了该领域近期频繁遭拒的趋势，而这些拒批已使该机构面临政治压力。